Methyl Drostanolone 10 mg

• Methyl Drostanolone 10 mg
• Brand: Magnus Pharmaceuticals
• Content: 100 tablets | 10 mg per tablet
• Manufactured in: Europe

Product Overview

Methyl Drostanolone 10 mg delivers the potent designer steroid known as Superdrol (methasterone), a 17--alkylated DHT-derived compound developed for strength and hypertrophy modeling in lab environments. With 3–5 the AR affinity of testosterone, it produces rapid muscle-mass and strength increases—balanced by a high risk of hepatotoxicity.

The compound’s ~8–10 h half-life and near-total oral bioavailability allow for precise oral-dosing studies. It remains banned under WADA S1, and detectable via long-term urinary markers.

Key Research Highlights

Extreme anabolic drive: Demonstrates superior androgen-receptor binding vs. testosterone, supporting explosive hypertrophy research

Fast-response protocols: 4–6 week dosing yields significant body-mass and nitrogen-retention gains in resistance-trained subjects

Non-aromatising structure: Prevents estrogenic water gain and gynecomastia, useful in lean-mass studies

Oral bioavailability ~100%: Allows high-efficiency delivery without injection models

High detection sensitivity: Novel 17-epi metabolites enable LC-MS/MS detection >2 weeks post-dose

WADA status: Fully banned as an S1 anabolic agent—any exposure will yield a positive doping test

Suggested Laboratory Applications

Strength-gain and lean-hypertrophy modeling

Nitrogen retention and glycogen utilization studies

Hepatotoxicity mechanism mapping

Anti-doping detection validation

Androgen–receptor activation assays

Technical Specifications

Documented Benefits

Lean muscle mass, strength, estrogenic water retention

Main Risks

Hepatotoxicity, jaundice, renal stress, lipid disruption, mood lability

Total Active Compound

1,000 mg per carton (10 mg 100 tablets)

Shelf-life

36 months (manufacturer specification)

Detection Window

> 14 days via LC-MS/MS urinary metabolites

PubChem-Supported Research Insights

Provides aggressive lean-mass and strength gain in short-cycle models

Non-aromatising design limits estrogen-related side effects

Documented in multiple hepatotoxicity and dyslipidaemia case reports

Maintains high androgenic activity with no estrogen conversion

Documented Research Side Effects

Cholestatic jaundice and hepatocellular stress after 2–7 weeks

Renal stress and hypertension reported in dose-escalation studies

HDL / LDL lipid shift, mood instability, and aggression risk

Virtually guaranteed anti-doping violation from metabolite trace detection

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 25°C in dry, light-protected conditionsPurchase confirms qualified researcher statusWADA-listed substance — doping test positive on any exposure